Next-generation cytokines for cancer immunotherapy
Open Access
- 1 April 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 4 (2), 123-133
- https://doi.org/10.1093/abt/tbab014
Abstract
Most studies focus on the first and second signals of T cell activation. However, the roles of cytokines in immunotherapy are not fully understood, and cytokines have not been widely used in patient care. Clinical application of cytokines is limited due to their short half-life in vivo, severe toxicity at therapeutic doses, and overall lack of efficacy. Several modifications have been engineered to extend their half-life and increase tumor targeting, including polyethylene glycol conjugation, fusion to tumor-targeting antibodies, and alteration of cytokine/cell receptor-binding affinity. These modifications demonstrate an improvement in either increased antitumor efficacy or reduced toxicity. However, these cytokine engineering strategies may still be improved further, as each strategy poses advantages and disadvantages in the delicate balance of targeting tumor cells, tumor-infiltrating lymphocytes, and peripheral immune cells. This review focuses on selected cytokines, including interferon-α, interleukin (IL)-2, IL-15, IL-21, and IL-12, in both preclinical studies and clinical applications. We review next-generation designs of these cytokines that improve half-life, tumor targeting, and antitumor efficacy. We also present our perspectives on the development of new strategies to potentiate cytokine-based immunotherapy.Keywords
This publication has 126 references indexed in Scilit:
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’Nature, 2012
- A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancerBritish Journal of Cancer, 2012
- Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor EnvironmentMolecular Therapy, 2011
- Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteasesImmunology, 2011
- Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted HostsCancer Research, 2010
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsProceedings of the National Academy of Sciences of the United States of America, 2010
- Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphomaBlood, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Interferon-alpha for maintenance of follicular lymphomaEmergencias, 2010
- IL-21–mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytesBlood, 2008